Biogen Inc banner

Biogen Inc
DUS:IDP

Watchlist Manager
Biogen Inc Logo
Biogen Inc
DUS:IDP
Watchlist
Price: 187.32 EUR 1.64% Market Closed
Market Cap: €27.3B

Wall St Price Targets

IDP Price Targets Summary
Biogen Inc

Wall Street analysts forecast IDP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IDP is 197.33 EUR with a low forecast of 133.52 EUR and a high forecast of 277.62 EUR.

Lowest Forecast
Price Target
133.52 EUR
29% Downside
Average Forecast
Price Target
197.33 EUR
5% Upside
Highest Forecast
Price Target
277.62 EUR
48% Upside
Biogen Inc Competitors:
Price Targets
SANA
Sana Biotechnology Inc
118% Upside
MEDP
Medpace Holdings Inc
-19% Downside
PTEN
Patterson-UTI Energy Inc
59% Upside

Revenue
Forecast

5% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 8 years is 2%.

Gross Profit
Forecast

3% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
3% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 8 years is 3%.

Operating Income
Forecast

2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 6%.

Pre-Tax Income
Forecast

-1% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss
-1% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 27%.

Net Income
Forecast

-1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss
-1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 8 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is IDP's stock price target?
Price Target
197.33 EUR

According to Wall Street analysts, the average 1-year price target for IDP is 197.33 EUR with a low forecast of 133.52 EUR and a high forecast of 277.62 EUR.

What is the Revenue forecast for Biogen Inc?
Projected CAGR
2%

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 8 years is 2%.

What is the Gross Profit forecast for Biogen Inc?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 8 years is 3%.

What is the Operating Income forecast for Biogen Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 6%.

What is the Pre-Tax Income forecast for Biogen Inc?
Projected CAGR
27%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 27%.

What is the Net Income forecast for Biogen Inc?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 8 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett